Drug intelligence / Profile preview

interferon alfacon-1 + ribavirin

Development stage: Unknown
Lead developer: InterMune
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous, Oral

Overview

Interferon alfacon-1 + ribavirin is a combination therapy used primarily for the treatment of chronic hepatitis C in adults with compensated liver disease. Interferon alfacon-1 is a recombinant type I interferon that binds to interferon alpha/beta receptor 1 (IFNAR1) and interferon alpha/beta receptor 2 (IFNAR2), activating Janus kinase 1 (JAK1) and tyrosine kinase 2 (Tyk2) and signal transducers and activators of transcription (STATs), leading to the expression of immunomodulatory and antiviral proteins. Ribavirin is a nucleoside analog with multiple mechanisms, including inhibition of inosine monophosphate dehydrogenase (IMPDH) resulting in depletion of GTP pools, direct inhibition of viral replication, induction of mutagenesis in viral genomes, and immunomodulation by shifting immune response toward Th1 phenotype. The combination has shown improved sustained virologic response rates compared to other interferons plus ribavirin regimens, especially in patients with genotype 1 hepatitis C virus infection and high viral load[2][3][4][5][6].

Brand names: Infergen (for consensus interferon alfa)Rebetol (for ribavirin)Copegus (for ribavirin)
Other names: consensus interferon and ribavirinCIFN and RBV

Targets

IFNAR (Immune system modulation via type I interferon receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)

Beyond the preview

Go deeper on interferon alfacon-1 + ribavirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on interferon alfacon-1 + ribavirin.

Explore the full profile